Meeting
2021 ASCO Annual Meeting
Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head and neck (H&N) cancer.
Authors
Daniel Osei-Fofie
Oncology Dept, Kimberley Hospital, Kimberley, South Africa
Daniel Osei-Fofie , Julie Wetter , Greg A. Landers , Peter Alfred Kraus , Shawgi Sukumaran , Hui Mun , Brian N. Stein , Victoria Jane Bray , Bomi Framroze , Jeffrey Gelfand , Paul Y. Song , Andries Lategan , Mikaela Dimitriu , Stephen T. Sonis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Other Head and Neck Cancer (Salivary, Thyroid)
Clinical Trial Registration Number
20180138
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 6075)
DOI
10.1200/JCO.2021.39.15_suppl.6075
Abstract #
6075
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
ROMAN: Reduction in oral mucositis with avasopasem manganese (GC4419)–phase III trial in patients receiving chemoradiotherapy for locally advanced, nonmetastatic head and neck cancer.
First Author: Jon Holmlund
Poster
2022 ASCO Annual Meeting
Phase 2 pilot trial of RRx-001 as an anti-mucositis agent in patients with head and neck cancer treated with chemoradiation (PREVLAR).
First Author: Marcelo Raul Bonomi
First Author: Tony R. Reid
Poster
2022 ASCO Annual Meeting
Phase 2, randomized, double-blind trial of EC-18 versus placebo to mitigate the development and time course of oral mucositis from concomitant chemoradiation for head and neck cancer.
First Author: Christina Henson